ReviewBioMed research international2014
Comparative evaluation of recombinant protein production in different biofactories: the green perspective.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Bluetongue in the Mediterranean Basin: An Overview of Recent Hotspots and Advances in Vaccine Technologies.Microorganisms · 2026Review
- An efficient lysate-based approach for biosynthesis of the pyrrolobenzodiazepine natural product tilimycin.Journal of biotechnology · 2025Article
- High-yield, plant-based production of an antimicrobial peptide with potent activity in a mouse model.Plant biotechnology journal · 2024Article
- Proteomic analysis reveals molecular changes following genetic engineering in Chlamydomonas reinhardtii.BMC microbiology · 2024Article
- Development of Virus-like Particle Plant-Based Vaccines against Avian H5 and H9 Influenza A Viruses.Veterinary sciences · 2024Article
- A Review of Rattlesnake Venoms.Toxins · 2023Review
- Review
- Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery: A Host Comparative Overview.Pharmaceutics · 2023Article
- An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.RSC medicinal chemistry · 2022Review
- Article
- Genetic Manipulation and Bioreactor Culture of Plants as a Tool for Industry and Its Applications.Molecules (Basel, Switzerland) · 2022Review
- Optimising expression and extraction of recombinant proteins in plants.Frontiers in plant science · 2022Review
- Immunoinformatic analysis of the whole proteome for vaccine design: An application toFrontiers in immunology · 2022Article
- Integrating plant molecular farming and materials research for next-generation vaccines.Nature reviews. Materials · 2022Review
- COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.Biomolecules · 2021Review
- Article
- Recombinant protein vaccines, a proven approach against coronavirus pandemics.Advanced drug delivery reviews · 2021Review
- Expression of BMP2-Hydrophobin fusion protein in the tobacco plant and molecular dynamic evaluation of its simulated model.Plant biotechnology reports · 2021Article
- High-level production in a plant system of a thermostable carbonic anhydrase and its immobilization on microcrystalline cellulose beads for COPlant cell reports · 2020Article
- Unprecedented enhancement of recombinant protein production in sugarcane culms using a combinatorial promoter stacking system.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the production of recombinant pharmaceutical proteins in heterologous systems has increased significantly. Most applications involve complex proteins and glycoproteins that are difficult to produce, thus promoting the development and improvement of a wide range of production platforms. No individual system is optimal for the production of all recombinant proteins, so the diversity of platforms based on plants offers a significant advantage. Here, we discuss the production of four recombinant pharmaceutical proteins using different platforms, highlighting from these examples the unique advantages of plant-based systems over traditional fermenter-based expression platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.